“We are very pleased to welcome Agneta to Pharmability. Her extensive experience in clinical project management and early-phase development strengthens our capacity as we advance TIR-C into its next stage of development and continue building a strong and experienced project team,” says Leo Holmgren, CEO of Pharmability.

Agneta Wennerholm

Agneta Wennerholm brings more than 25 years of experience in clinical development across pharmaceutical and biotechnology companies and clinical CROs in a broad range of therapeutic areas. She has a long track record working with Swedish biotech companies in early-phase clinical trials.

Agneta will lead the company’s clinical development activities and support preparations for the upcoming first-in-human clinical trial, working closely with internal teams and external partners to ensure efficient, high-quality execution.